ArticleIranian journal of basic medical sciences2026
Protein kinase C θ deletion ameliorates bleomycin-induced pulmonary fibrosis via the improvement of SIRT1/AMPK signaling on autophagy and senescence.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Protein kinase C theta (PKC θ) is involved in the regulation of various inflammatory diseases, such as allergic asthma and ConA-induced hepatitis. However, its role in pulmonary fibrosis has not been reported. This study aimed to explore the role of PKC θ in bleomycin-induced pulmonary fibrosis and the potential mechanisms involved. Materials and Methods: WT C57BL/6 and PKC-θ deletion mice were administered a single intratracheal injection of bleomycin at a dosage of 3 mg/kg to prepare an animal model of pulmonary fibrosis. Histopathological changes of lung fibrosis were observed. Blood samples and BALF were collected for biochemical analysis. Protein expression in lung tissues was assessed to investigate a potential mechanism of PKC θ in pulmonary fibrosis. Results: The results suggested that PKC θ knockout improved pulmonary structure and fibrosis through down-regulating the expression of collagen I and fibronectin, and the TGF-β1 pathway. PKC θ knockout significantly reduced the levels of the inflammatory factors TNF-α, IL-6, and TGF-β in BALF and lung tissues and the NF-κB/IκB-α pathway in the lung. PKC θ knockout also elevated the activities of antioxidant enzymes SOD and CAT, and improved the SIRT1/AMPK-HO-1/Nrf2 pathway. Further, PKC θ knockout ameliorated the expression of the autophagy-related proteins Beclin 1 and p62, and the senescence markers p53 and p21. Conclusion: These data showed that the improvement in PKC θ knockout in pulmonary fibrosis was associated with enhanced anti-inflammatory and antioxidant effects, activation of autophagy, and reduced senescence effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.